secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2024-12-20T23:59:59+00:00
Accession:  0001437749-24-038020
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton Pharma closes $22.5M Increlex acquisition; expands credit facility
-----------------------------------------------------------------------

- Acquired Increlex (mecasermin) from Ipsen for $22.5M at closing plus $8.7M inventory; $2.5M due on first and second anniversaries.
- Credit facility with SWK expanded by $25.7M to $30M, maturity to 3 years, SOFR+6.75%; warrant for 289,736 shares at $5.32 issued.
- Increlex is the only FDA/EMA approved treatment for severe primary IGF-1 deficiency in pediatric patients aged 2+.
- U.S. available via AnovoRx specialty pharmacy; Eton to commercialize outside U.S. after 6-month transition.
- Additional inventory purchase obligation up to EUR 15.0 million over 30 months; transaction financed by cash and credit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774924038020/0001437749-24-038020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774924038020/eton20241215_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-038020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer